Among patients with MCL still on study in January 2025, 35.3% reported improved MCL-related symptoms, while 5.9% reported ...

Margaret Krackeler, MD, discusses real-world data supporting the switch from ibrutinib to zanubrutinib for chronic lymphocytic leukemia.

Ariana Levin, MD, assistant professor in the Department of Ophthalmology at NYU Grossman School of Medicine, discussed how open communication between the ophthalmologist or optometrist and their ...

Adults with nonmelanoma skin cancer reported higher unadjusted levels of day-to-day mental distress, but adjusted analyses showed no significant association with depression and a slight decrease in ...

The HELIOS-B trial previously showed that vutrisiran (Amvuttra; Alnylam Pharmaceuticals), a gene-silencing therapy that ...

Dermatology is entering a "biological revolution," with engineered tissues and bio-machines offering new therapeutic ...

An article published in TechTarget referenced a study published in the January 2026 issue of The American Journal of Managed ...

This transcript has been lightly edited for clarity; captions are auto-generated.

ASH 2025 immunotherapy data highlight the importance of treatment sequencing, real-world outcomes in high-risk populations, ...

Manjool Shah, MD, clinical associate professor of ophthalmology and visual sciences for the Kellogg Eye Center, discussed how ...

Data at ASH 2025 highlighted that standardized workflows, education, monitoring innovations, and collaboration are steadily ...

Adopting zanubrutinib for the treatment of chronic lymphocytic leukemia showed improved tolerability and persistence, ...